Neumora Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2024 was $-0.34.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.42.
During the past 3 years, the average EPS without NRIGrowth Rate was -77.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 5 years, Neumora Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -77.10% per year. The lowest was -77.10% per year. And the median was -77.10% per year.
Neumora Therapeutics EPS (Diluted) Historical Data
The historical data trend for Neumora Therapeutics's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Neumora Therapeutics's EPS (Diluted)
For the Biotechnology subindustry, Neumora Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neumora Therapeutics's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neumora Therapeutics's PE Ratio distribution charts can be found below:
* The bar in red indicates where Neumora Therapeutics's PE Ratio falls into.
Neumora Therapeutics EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Neumora Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Neumora Therapeutics EPS (Diluted) Related Terms
Thank you for viewing the detailed overview of Neumora Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Neumora Therapeutics (Neumora Therapeutics) Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMRA has been successfully added to your 